ONCOVITA, a biotechnology company specializing in innovative vaccine development and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals, a global leader in sterile unit-dose manufacturing, have formed a strategic partnership to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children.
This collaboration combines Measovir, ONCOVITA’s proprietary platform designed to develop highly immunogenic vaccines, with Euroject, UNITHER Pharmaceuticals’ Blow-Fill-Seal (BFS)-based single-dose injection system for the direct administration of vaccines and biologics. The objective is to provide an effective, economical, and accessible solution, suitable for large-scale production.
Dr Jean-François Le Bigot, President of ONCOVITA, said: “We design innovative vaccines using a disruptive technology, with the ambition of proving the concept in humans and then bringing these advances to the bedside in partnership with pharma companies. This partnership with Unither allows us to explore the integration of Measovir® and Euroject® for simplified administration of a vaccine based on a live attenuated measles strain. Our objective: an effective, safe and easy-to-deploy solution to better protect patients worldwide.”
Eric Goupil, President of Unither Pharmaceuticals, said: “We firmly believe that combining the Measovir® technology with the Euroject® device represents a major breakthrough in making vaccination simpler, safer, and more effective at large scale. By facilitating vaccine administration and improving accessibility, we contribute to enhancing and simplifying patients’ lives while addressing today’s and tomorrow’s global public health challenges.”
